JP7323179B2 - 排出ポンプ阻害剤としてのインドール誘導体 - Google Patents

排出ポンプ阻害剤としてのインドール誘導体 Download PDF

Info

Publication number
JP7323179B2
JP7323179B2 JP2019549454A JP2019549454A JP7323179B2 JP 7323179 B2 JP7323179 B2 JP 7323179B2 JP 2019549454 A JP2019549454 A JP 2019549454A JP 2019549454 A JP2019549454 A JP 2019549454A JP 7323179 B2 JP7323179 B2 JP 7323179B2
Authority
JP
Japan
Prior art keywords
alkyl
carbocyclyl
aryl
heteroaryl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510044A5 (cg-RX-API-DMAC7.html
JP2020510044A (ja
Inventor
エドモンド ジェイ． ラヴォイ，
アジット ケー． パルヒ，
イー ユアン，
ヨンジェン ジャン，
ヤンシェン スン，
Original Assignee
ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー filed Critical ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー
Publication of JP2020510044A publication Critical patent/JP2020510044A/ja
Publication of JP2020510044A5 publication Critical patent/JP2020510044A5/ja
Application granted granted Critical
Publication of JP7323179B2 publication Critical patent/JP7323179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP2019549454A 2017-03-10 2018-03-09 排出ポンプ阻害剤としてのインドール誘導体 Active JP7323179B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762469987P 2017-03-10 2017-03-10
US62/469,987 2017-03-10
US201762523154P 2017-06-21 2017-06-21
US62/523,154 2017-06-21
PCT/US2018/021848 WO2018165611A1 (en) 2017-03-10 2018-03-09 Indole derivatives as efflux pump inhibitors

Publications (3)

Publication Number Publication Date
JP2020510044A JP2020510044A (ja) 2020-04-02
JP2020510044A5 JP2020510044A5 (cg-RX-API-DMAC7.html) 2021-04-15
JP7323179B2 true JP7323179B2 (ja) 2023-08-08

Family

ID=62044950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549454A Active JP7323179B2 (ja) 2017-03-10 2018-03-09 排出ポンプ阻害剤としてのインドール誘導体

Country Status (12)

Country Link
US (1) US11993571B2 (cg-RX-API-DMAC7.html)
EP (1) EP3592736A1 (cg-RX-API-DMAC7.html)
JP (1) JP7323179B2 (cg-RX-API-DMAC7.html)
KR (1) KR102697360B1 (cg-RX-API-DMAC7.html)
CN (1) CN110770224B (cg-RX-API-DMAC7.html)
AU (1) AU2018231120B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018691A2 (cg-RX-API-DMAC7.html)
CA (1) CA3061238A1 (cg-RX-API-DMAC7.html)
IL (1) IL269210B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019010717A (cg-RX-API-DMAC7.html)
SG (1) SG11201908351TA (cg-RX-API-DMAC7.html)
WO (1) WO2018165611A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147335A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2017147333A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
AU2018231120B2 (en) 2017-03-10 2022-06-23 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
WO2018165614A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018165612A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
EP3630109A4 (en) 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey BACTERIAL EFFLUX PUMP INHIBITORS
US11458121B2 (en) 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
WO2019099402A1 (en) * 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
KR102704123B1 (ko) 2019-11-01 2024-09-06 에스엘 주식회사 차량용 램프
WO2025043115A1 (en) 2023-08-23 2025-02-27 Taxis Pharmaceuticals, Inc. Bacterial efflux pump inhibitors
WO2025049604A1 (en) * 2023-08-29 2025-03-06 Maze Therapeutics, Inc. Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511414A (ja) 1999-10-08 2003-03-25 スミスクライン・ビーチャム・コーポレイション ＦａｂＩ阻害剤
US20090215828A1 (en) 2008-02-22 2009-08-27 Grunenthal Gmbh Substituted indole derivatives
WO2012084971A1 (fr) 2010-12-20 2012-06-28 Centre National De La Recherche Scientifique (Cnrs) Derives d'indoles en tant qu'agents contre des bacteries a gram negatif et positif
WO2014078294A1 (en) 2012-11-13 2014-05-22 Memorial Sloan-Kettering Cancer Center Indole compounds and their use as antimicrobials
WO2015164482A1 (en) 2014-04-22 2015-10-29 The Johns Hopkins University Inhibitors of drug-resistant mycobacterium tuberculosis
WO2017023894A1 (en) 2015-08-03 2017-02-09 Raze Therapeutics, Inc. Mthfd2 inhibitors and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
US3465080A (en) * 1968-10-07 1969-09-02 American Cyanamid Co Therapeutic compositions containing morpholinoalkylene - indoles and methods of administering such in the treatment of depression
US3978224A (en) 1975-07-01 1976-08-31 Schering Corporation Antimicrobial halo-substituted-2-cyanoethylaminoalkyl-3-phenyl-indoles
US4910193A (en) * 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1992004017A1 (en) 1990-09-10 1992-03-19 The Upjohn Company Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
US5663152A (en) 1995-01-19 1997-09-02 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators for aminoglycosides
US6506339B1 (en) * 1997-02-10 2003-01-14 Biomedical Design, Inc. Method of sterilization
WO1999037667A1 (en) * 1998-01-23 1999-07-29 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6204279B1 (en) 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
US6326391B1 (en) 1998-12-04 2001-12-04 Influx, Inc. Inhibitors of multidrug transporters
US6730684B1 (en) * 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6555569B2 (en) 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
WO2011101710A1 (en) 2010-02-16 2011-08-25 Wockhardt Research Centre Efflux pump inhibitors
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
HUP0103986A2 (hu) * 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
WO2004062674A2 (en) 2003-01-07 2004-07-29 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
AU2005245962A1 (en) 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
US7855228B2 (en) 2005-02-10 2010-12-21 The Board Of Trustees Of The Leland Stamford Junior University Antibiotics targeting MreB
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
FR2904317A1 (fr) * 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
CA2927045A1 (en) 2006-10-03 2008-04-10 Muthiah Manoharan Lipid containing formulations
WO2009110002A1 (en) 2008-03-05 2009-09-11 Council Of Scientific & Industrial Research Novel efflux pump inhibitors
WO2010033168A2 (en) 2008-09-18 2010-03-25 Renovis, Inc. Amide compounds, compositions and uses thereof
EP2414368B1 (en) 2009-04-03 2013-11-27 Achillion Pharmaceuticals, Inc. Hydroxythienoquinolones and related compounds as anti-infective agents
EP2394653A1 (en) * 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
JP6223452B2 (ja) 2012-09-07 2017-11-01 ノバルティス アーゲー インドールカルボキサミド誘導体およびその使用
CA2960275A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Smyd inhibitors
US9926261B2 (en) 2015-03-10 2018-03-27 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US9950993B2 (en) 2015-03-13 2018-04-24 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
EP3307725A1 (en) 2015-06-11 2018-04-18 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
WO2017147335A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2017147333A1 (en) 2016-02-24 2017-08-31 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
ES2968227T3 (es) * 2016-12-23 2024-05-08 Aquinnah Pharmaceuticals Inc Compuestos, composiciones y procedimientos de uso
AU2018231120B2 (en) 2017-03-10 2022-06-23 Rutgers, The State University Of New Jersey Indole derivatives as efflux pump inhibitors
WO2018165614A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2018165612A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
EP3630109A4 (en) 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey BACTERIAL EFFLUX PUMP INHIBITORS
US11458121B2 (en) * 2017-06-26 2022-10-04 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
US20190031624A1 (en) 2017-07-28 2019-01-31 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
WO2019099402A1 (en) * 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511414A (ja) 1999-10-08 2003-03-25 スミスクライン・ビーチャム・コーポレイション ＦａｂＩ阻害剤
US20090215828A1 (en) 2008-02-22 2009-08-27 Grunenthal Gmbh Substituted indole derivatives
WO2012084971A1 (fr) 2010-12-20 2012-06-28 Centre National De La Recherche Scientifique (Cnrs) Derives d'indoles en tant qu'agents contre des bacteries a gram negatif et positif
WO2014078294A1 (en) 2012-11-13 2014-05-22 Memorial Sloan-Kettering Cancer Center Indole compounds and their use as antimicrobials
WO2015164482A1 (en) 2014-04-22 2015-10-29 The Johns Hopkins University Inhibitors of drug-resistant mycobacterium tuberculosis
WO2017023894A1 (en) 2015-08-03 2017-02-09 Raze Therapeutics, Inc. Mthfd2 inhibitors and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY，2009年08月，pp. 3181-3189
Antimicrobial Agents and Chemotherapy，2011年05月09日，66，pp. 1417-1430
Bellemin, R. et al.，New indole derivatives as ACAT inhibitors: synthesis and structure-activity relationships，European Journal of Medicinal Chemistry，1996年，vol.31，pp.123-132
Drug Discovery Today，2017年01月13日，Volume 22, Number 3，文献公知日：2017年3月16日
Millson, David S.et al.，Migraine pharmacotherapy with oral triptans: a rational approach to clinical management，Expert Opinion on Pharmacotherapy，2000年，vol.1, no.3，pp.391-404
Olgen, Sureyya et al.，Synthesis of new indole-2-carboxamide and 3-acetamide derivatives and evaluation their antioxidant properties，Journal of Enzyme Inhibitation and Medicinal Chemistry，2013年，vol.28, no.1，pp.58-64
日本内科学会雑誌，2013年11月10日，第102巻、第11号

Also Published As

Publication number Publication date
US11993571B2 (en) 2024-05-28
IL269210A (en) 2019-11-28
EP3592736A1 (en) 2020-01-15
WO2018165611A1 (en) 2018-09-13
MX2019010717A (es) 2019-12-05
AU2018231120B2 (en) 2022-06-23
CA3061238A1 (en) 2018-09-13
SG11201908351TA (en) 2019-10-30
KR20190138790A (ko) 2019-12-16
IL269210B1 (en) 2025-01-01
KR102697360B1 (ko) 2024-08-20
US20210094912A1 (en) 2021-04-01
IL269210B2 (en) 2025-05-01
BR112019018691A2 (pt) 2020-04-07
JP2020510044A (ja) 2020-04-02
CN110770224A (zh) 2020-02-07
CN110770224B (zh) 2022-11-18
AU2018231120A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7323179B2 (ja) 排出ポンプ阻害剤としてのインドール誘導体
JP7281822B2 (ja) 細菌の排出ポンプ阻害剤
US5420155A (en) Tetramic acid derivatives
US9394250B2 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
US11180459B2 (en) Bacterial efflux pump inhibitors
WO2018165614A1 (en) Bacterial efflux pump inhibitors
WO2019099402A1 (en) Therapeutic compounds and methods to treat infection
US20160271082A1 (en) Bacterial efflux pump inhibitors
WO2019005841A1 (en) THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
BR112014003146B1 (pt) 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com homopiperidinila antibacterianas, composição farmacêutica compreendendo os referidos composto e processos para preparação destes
WO2021243273A1 (en) Bacterial efflux pump inhibitors
HK40020543B (en) Indole derivatives as efflux pump inhibitors
WO2025043115A1 (en) Bacterial efflux pump inhibitors
HK40020543A (en) Indole derivatives as efflux pump inhibitors
HK40028701A (en) Bacterial efflux pump inhibitors
CN118251394A (zh) 治疗性化合物
HK40072575A (en) Pharmaceutical composition useful in inhibiting idh1
HK1198439A1 (en) Lactam derivates useful as inhibitors of mutant idh1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230720

R150 Certificate of patent or registration of utility model

Ref document number: 7323179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150